Yahong Pharma completed a D-round financing of more than RMB700 million

11, 2020, Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Yahong Pharmaceuticals"), announced the completion of the D-round financing. This round of financing by Qiming Venture Capital, Yunfeng Fund, ZHONGC Capital's Zhongjin Chuanhua Fund, One Village Capital, Hengxu Capital, Hongxin Capital, Gopher Assets, Jianfa Emerging Investment, Hanrun Capital, Qinzhi Capital, About India Fund, Yu Shuo De ear, etc. to participate in the investment, the transaction amount of more than 700 million yuan. As early as June this year, Yahong Pharmaceuticals has just completed the C-plus round of financing, further accelerating the pace of business.Yahong Pharmaceuticals is a global and innovative pharmaceutical research and development company focused on the urinary system anti-tumor and related diseases, since its establishment in 2010, Yahong Pharmaceuticals has continued to focus on the field of the urinary system in-depth layout, and constantly enrich the research and development platform and product pipeline, with a number of clinical and preclinical development stage of the project.It is reported that the funds raised by Yahong Pharmaceuticals this round will be used to support the development of the company's existing pipeline products, the construction of technology platforms, as well as accelerate the commercialization and industrialization. APL-1202, one of the key projects of Yahong Pharmaceuticals, is a product for the treatment of non-myocardial immersion bladder cancer and is the first oral, reversible methionine amino peptidease TYPE II (MetAP2) inhibitor to enter Phase III clinical studies. APL-1202 will help patients avoid or delay the fate of full bladder cut as part of a new anti-tumor mechanism. At present, APL-1202 and chemotherapy perfusion in combination with the treatment of chemotherapy perfusion recurrence of medium- and high-risk non-muscle layer immersion bladder cancer in China Phase III clinical trials have been completed, and ready to be used with immunotherapy drugs into the Sino-US Phase II clinical trials. Last month, a Phase III clinical trial application for APL-1202 single-drug first-line treatment of critical non-muscle immersive bladder cancer was approved in China.Another photodynamic pharmaceutical combination product for non-surgical treatment of cervical high-level scaly endotrine lesions, APL-1702 (Cevira®), has been approved for international multi-center Phase III clinical trials and will be the world's first drug delivered in the near future. APL-1702 will provide female patients in China and around the world with a new treatment option in addition to surgical treatment, freeing some patients from the pain and side effects of surgical treatment, especially the effects of surgery on reproductive function.APL-1501, an independent research and development product developed by Ahong Pharmaceuticals through its modified New Drug Research and Development Technology Platform (PADD), has recently been approved by the Australian regulatory authorities to officially launch Phase I clinical trials. As a second-generation product of APL-1202, APL-1501 will expand its clinical adaptations, such as prostate cancer, urinary tract infections, etc., and be used in the development of global markets.“ We are proud to be recognized and supported by the country's leading investment institutions and to have completed round D financing quickly. The completion of this financing also marks the official entry of Yahong Medicine into a new stage of development. Dr. Pan Ke, Founder and CEO of Yahong Pharmaceuticals, said, "In addition to continuously improving its research and development capabilities, Yahong Pharmaceuticals has begun commercial preparations, and will also start the construction of production bases to prepare for the launch of a number of research products that are about to complete clinical trials or declare new drug certificates, and strive to bring better therapeutic drugs and means to China and the global market at an early stage for the benefit of more patients." (Shell Society
)